Breaking News Instant updates and real-time market news.

KPTI

Karyopharm

$12.57

0.86 (7.34%)

07:32
11/04/19
11/04
07:32
11/04/19
07:32

Karyopharm expects topline data from Phase 3 portion of SEAL stduy in 2020

Karyopharm previously reported positive results from the Phase 2 portion of the randomized, blinded Phase 2/3 SEAL study evaluating single-agent selinexor versus placebo in patients with previously treated, advanced unresectable dedifferentiated liposarcoma. Enrollment is currently ongoing in the Phase 3 portion of the SEAL study. Top-line data from the Phase 3 portion of the SEAL study are anticipated in 2020. Assuming a positive outcome on the primary endpoint of PFS, the Company intends to use the data from the SEAL study to support NDA and MAA submissions requesting approval for selinexor for patients with advanced unresectable dedifferentiated liposarcoma.

  • 04

    Nov

  • 07

    Dec

KPTI Karyopharm
$12.57

0.86 (7.34%)

07/23/19
JPMS
07/23/19
UPGRADE
Target $16
JPMS
Overweight
Karyopharm upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Eric Joseph upgraded Karyopharm Therapeutics to Overweight from Neutral and doubled his price target for the shares to $16 from $8. The analyst says his doctor survey supports a "strong" Xpovio launch and long-term outlook.
07/23/19
JPMS
07/23/19
UPGRADE
Target $16
JPMS
Overweight
JPMorgan upgrades Karyopharm after doctor survey, doubles price target
JPMorgan analyst Eric Joseph upgraded Karyopharm Therapeutics to Overweight from Neutral and doubled his price target for the shares to $16 from $8. The analyst conducted a U.S. physician survey assessing Xpovio anticipated use in the approved indication of penta-refractory myeloma, as well as expectations around use in earlier-line settings. The survey of 15 doctors data show favorable reception to Xpovio's clinical profile, with 75% respondents intending to write Xpovio for PR-MM within the next 12 months, Joseph tells investors in a research note. Importantly, nearly all respondents described the side-effect profile as manageable, which is "very encouraging," adds the analyst. He sees a favorable reward/risk profile for Karyopharm shares at current levels.
07/23/19
07/23/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) upgraded to Buy from Hold at Stifel with analyst John Egbert saying the company's sales reorganization efforts were already reflected in its prior guidance and the daily active user checks for the quarter appear to be positive. 2. Murphy Oil (MUR) upgraded to Buy from Neutral at Goldman Sachs with analyst Brian Singer saying he believes the company's free cash flow generation is being underappreciated by the market. 3. Karyopharm (KPTI) upgraded to Overweight from Neutral at JPMorgan with analyst Eric Joseph saying he conducted a U.S. physician survey assessing Xpovio anticipated use in the approved indication of penta-refractory myeloma, as well as expectations around use in earlier-line settings. The survey of 15 doctors data show favorable reception to Xpovio's clinical profile, with 75% respondents intending to write Xpovio for PR-MM within the next 12 months. 4. Smith & Nephew (SNN) upgraded to Buy from Hold at Berenberg with analyst Tom Jones saying he believes management and process changes have addressed the company's execution issues. He views Smith & Nephew's portfolio as "highly competitive." 5. Columbia Sportswear (COLM) upgraded to Buy from Neutral at BofA/Merrill with analyst Alexander Perry citing his outlook for the company to generate "significant near-term revenue and EPS upside" amid a strong wholesale environment for Columbia's apparel as well as its "significant" under-penetration in footwear. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/24/19
BARD
09/24/19
NO CHANGE
Target $25
BARD
Outperform
Karyopharm Xpovio launch appears strong, says Baird
Baird analyst Michael Ulz said his physician survey regarding the Karyopharm launch of Xpovio is indicating strong early trends. The analyst said there appears to be an early robust, broad adoption with meaningful share gains ahead, and the safety profile is manageable. Ulz said he sees upside to estimates and he reiterated his Outperform rating and $25 price target on Karyopharm shares.

TODAY'S FREE FLY STORIES

BIO

Bio-Rad

$354.69

-8.005 (-2.21%)

16:56
12/13/19
12/13
16:56
12/13/19
16:56
Hot Stocks
Bio-Rad progressing from ransomware attack recovery detected on Dec 5th »

Bio-Rad Laboratories…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

16:50
12/13/19
12/13
16:50
12/13/19
16:50
Hot Stocks
Amarin confirms FDA approval of Vascepa »

Amarin announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

FRTA

Forterra

$10.69

0.11 (1.04%)

16:46
12/13/19
12/13
16:46
12/13/19
16:46
Syndicate
Breaking Syndicate news story on Forterra »

Forterra files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

16:45
12/13/19
12/13
16:45
12/13/19
16:45
Hot Stocks
Amarin receives FDA approval of Vascepa »

The U.S. FDA approved the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

SPY

SPDR S&P 500 ETF Trust

$317.27

0.13 (0.04%)

, SPX

S&P 500

$0.00

(0.00%)

16:37
12/13/19
12/13
16:37
12/13/19
16:37
Periodicals
SCOTUS to hear three cases on Trump's financial records, CNBC reports »

The U.S. Supreme Court…

SPY

SPDR S&P 500 ETF Trust

$317.27

0.13 (0.04%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CME

CME Group

$204.61

1.47 (0.72%)

16:34
12/13/19
12/13
16:34
12/13/19
16:34
Hot Stocks
CME Group CEO Duffy sells 39,309 class A common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

GLG

China Bat Group

$1.81

-0.055 (-2.95%)

16:33
12/13/19
12/13
16:33
12/13/19
16:33
Hot Stocks
China Bat Group regains compliance with Nasdaq »

China Bat Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPX

WPX Energy

$10.92

-0.24 (-2.15%)

16:32
12/13/19
12/13
16:32
12/13/19
16:32
Periodicals
WPX Energy in talks to acquire Felix Energy assets for $2.5B, Bloomberg says »

WPX Energy is in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

HZNP

Horizon Pharma

$32.84

(0.00%)

16:30
12/13/19
12/13
16:30
12/13/19
16:30
Hot Stocks
Breaking Hot Stocks news story on Horizon Pharma »

Horizon Pharma trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 08

    Mar

16:30
12/13/19
12/13
16:30
12/13/19
16:30
Options
Preliminary option volume of 31.3M today »

Preliminary option volume…

ORCL

Oracle

$54.49

-1.98 (-3.51%)

, ADBE

Adobe

$316.89

11.13 (3.64%)

16:27
12/13/19
12/13
16:27
12/13/19
16:27
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks were on a…

ORCL

Oracle

$54.49

-1.98 (-3.51%)

ADBE

Adobe

$316.89

11.13 (3.64%)

RBS

RBS

$6.81

0.65 (10.55%)

BCS

Barclays

$9.73

0.65 (7.16%)

LYG

Lloyds Banking

$3.43

0.235 (7.37%)

T

AT&T

$38.24

-0.11 (-0.29%)

LYV

Live Nation

$64.23

-5.21 (-7.50%)

SRPT

Sarepta

$132.00

31.61 (31.49%)

TNDM

TNDM

ATNX

Athenex

$14.56

-2.38 (-14.05%)

AVGO

Broadcom

$315.37

-12.02 (-3.67%)

COST

Costco

$291.88

-5.62 (-1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 23

    Jan

  • 29

    Jan

  • 05

    Mar

VKTX

Viking Therapeutics

$7.94

0.045 (0.57%)

16:26
12/13/19
12/13
16:26
12/13/19
16:26
Conference/Events
Viking Therapeutics management to meet with SVB Leerink »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

VCYT

Veracyte

$28.50

-0.16 (-0.56%)

16:24
12/13/19
12/13
16:24
12/13/19
16:24
Conference/Events
Veracyte management to meet with SVB Leerink »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

  • 17

    Dec

MCK

McKesson

$140.56

-3.44 (-2.39%)

16:21
12/13/19
12/13
16:21
12/13/19
16:21
Conference/Events
McKessonto hold a sell-side analyst meeting »

Sell-Side Analyst Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

MDR

McDermott

$0.82

0.0412 (5.31%)

16:20
12/13/19
12/13
16:20
12/13/19
16:20
Hot Stocks
McDermott discloses NYSE delisting notice »

McDermott announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICPT

Intercept

$114.26

-1.52 (-1.31%)

16:20
12/13/19
12/13
16:20
12/13/19
16:20
Conference/Events
Intercept to hold a meeting for investors »

Management holds NASH…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

  • 26

    Mar

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
12/13/19
12/13
16:20
12/13/19
16:20
Options
Closing CBOE SPX and VIX Index summary for December 13th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPWR

Ideal Power

$2.45

0.04 (1.66%)

16:19
12/13/19
12/13
16:19
12/13/19
16:19
Syndicate
Breaking Syndicate news story on Ideal Power »

Ideal Power files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERIE

Erie Indemnity

$168.97

0.25 (0.15%)

16:18
12/13/19
12/13
16:18
12/13/19
16:18
Hot Stocks
Erie Indemnity increases quarterly dividend »

The board of Erie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

ESRT

Empire State Realty

$13.68

0.055 (0.40%)

16:17
12/13/19
12/13
16:17
12/13/19
16:17
Hot Stocks
Empire State Realty renews $500M stock repurchase program »

Empire State Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HST

Host Hotels

$17.95

0.09 (0.50%)

16:17
12/13/19
12/13
16:17
12/13/19
16:17
Hot Stocks
Host Hotels declares special dividend of 5c per share »

Host Hotels & Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
12/13/19
12/13
16:17
12/13/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
12/13/19
12/13
16:16
12/13/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PACW

PacWest Bancorp

$38.11

-0.54 (-1.40%)

16:14
12/13/19
12/13
16:14
12/13/19
16:14
Hot Stocks
PacWest Bancorp CEO buys 6.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICPT

Intercept

$114.03

-1.75 (-1.51%)

16:13
12/13/19
12/13
16:13
12/13/19
16:13
Conference/Events
Intercept to hold a meeting for investors »

Management holds NASH…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.